Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

4d Molecular Therapeutics, Inc. (FDMT)

Sector - Healthcare

Price chart

+80.78%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage gene therapy company pioneering the development of product candidates using their targeted and evolved AAV vectors. They have built a deep portfolio of gene therapy product candidates initially focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). They have three product candidates that are in clinical trials. They are developing 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), currently in a Phase 1/2 clinical trial with initial clinical data expected in 2021. They are advancing 4D-110 for the treatment of choroideremia, currently in a Phase 1 clinical trial with initial clinical data expected in 2022. Roche holds an exclusive worldwide license to 4D-110 and has the exclusive option to in-license 4D-125 prior to initiation of pivotal clinical trials. They received FDA Fast Track designation for 4D-310 for the treatment of Fabry disease, which is currently in a Phase 1/2 clinical trial, with initial clinical data expected in 2021. Their two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration (wet AMD), and 4D-710 for the treatment of cystic fibrosis lung disease. They expect to file the INDs and to initiate clinical trials for both of these programs in the second half of 2021.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
David Kirn August Moretti
Employees Founded
57 2013

Contacts

Address: 5858 Horton Street #455, Emeryville, CA 94608, US

Telephone: (510) 505-2680

Web page: http://www.4dmoleculartherapeutics.com

IPO information

Expected Date 12/11/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $20.00-$22.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4.8
Shares Revised (MM) 8.4
Expected offer amount (MM) $100.8
Realized offer amount(MM) $193.2

Financial Data (last reporting year)

Market Cap (MM) $536.2
Revenues (MM) $13.5
Net Income (Loss) (MM) $-20.9

Voting

What do you think will happen with the FDMT share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Goldman Sachs/ BofA Securities/ Evercore
CO-Managers
-

Sector: Healthcare

Tweets about $FDMT

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats